Iroko acquires Canadian rights to Eli Lilly’s Vancocin

Vancocin is a potent antibiotic indicated to treat two significant bacterial infections of the lower digestive tract, including diseases caused by Clostridium difficile, one of the most common bacteria found in hospitals and long-term care facilities. According to the Public Health Agency of Canada, Clostridium difficile can put the elderly and those requiring prolonged use of antibiotics at greatest risk of infection.

John Vavricka, Iroko’s president and CEO, said: “This acquisition further augments Iroko’s product portfolio and gives us the opportunity to extend our global footprint into Canada. We are very pleased to acquire and continue selling this important medicine.”